QQ客服 官方微博 反馈留言

	RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study
	Chen Youxin; Sharma Tarun; Li Xiaorong; Song Yanping; Chang Qing; Lin Renxin; Egger Anna; Foo Arthur; Gekkieva Margarita; Lai Timothy Y Y
	2019
卷号	39期号:10页码:1985-1994
ISSN号	1539-2864
DOI	10.1097/IAE.0000000000002292
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6346124
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Chen Youxin,Sharma Tarun,Li Xiaorong,et al. RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study[J],2019,39(10):1985-1994.
APA	Chen Youxin.,Sharma Tarun.,Li Xiaorong.,Song Yanping.,Chang Qing.,...&Lai Timothy Y Y.(2019).RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study.,39(10),1985-1994.
MLA	Chen Youxin,et al."RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study".39.10(2019):1985-1994.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。